Special Issue "Gut Microbiome and Human Diseases"
A special issue of Diseases (ISSN 2079-9721).
Deadline for manuscript submissions: closed (31 December 2018).
Interests: gut microbiome; liver disease; metagenomics; metabolomics; alcoholic liver disease; nonalcoholic steatohepatitis(NASH); liver cirrhosis and hepatocellular carcinoma
Special Issues and Collections in MDPI journals
Medlab Clinical Ltd, Sydney, Australia
Interests: Intestinal microbiome, probiotics, immune function, Metabolic Disorders, Mood Disorders, Cancer
The Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, School of Medicine, University of Sydney, Australia
Medlab Clinical Ltd, Sydney, Australia
Interests: Gut Microbiome, Non-alcoholic fatty liver disease, Metabolic Syndrome
The gut microbiome is the most densely populated microbial site on or within the human body. With at least 1000 different species of microbes residing in the human gastrointestinal tract (GIT), host-microbial crosstalk contributes to the maintenance of a homeostatic relationship between the two parties. The gut microbiome exerts immunological, protective and metabolic effects on the host, with a disruption to the balanced relationship posited to be involved in the pathogenesis of various diseases including liver, intestinal, metabolic, mental and immunological disorders. Intestinal epithelial cell dysbiosis linked to adverse shifts in the intestinal microbiome and their products is characterised by increased intestinal permeability and enhanced microbial translocation. Animal and human studies have confirmed the role of intestinal epithelial cell dysbiosis in the manifestation of metabolic syndrome and associated complications, including non-alcoholic fatty liver disease (NAFLD). The posited mechanism of action is that microbial translocation due to increased intestinal permeability can induce a state of metabolic endotoxemia when bacteria and bacterial fragments leak into systemic circulation and cultivate a pro-inflammatory environment in various organs. Low-grade chronic systemic inflammation not only provokes immunological disturbances but also contributes to the development of insulin resistance, type 2 diabetes mellitus and other obesity-related complications. Gut microbiome has further substantial impacts on cancer development.
This special issue, titled ‘Gut Microbiome and Human Diseases’, will aim to explore the current understanding of the role of the gut microbiome in the pathogenesis of liver, intestine, metabolic, mental and immunological disorders as well as research exploring how the gut microbiome can be manipulated with probiotics/prebiotics and antibiotics designated as adjunct medicines could beneficially help to treat these variable human diseases.
Prof. Dr. Hiroshi Fukui
Prof. Dr. Luis Vitetta
Ms. Emma Tali Saltzman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gut microbiome
- liver diseases
- non-alcoholic fatty liver disease (NAFLD)
- type 2 Diabetes Mellitus (T2DM)
- metabolic Syndrome (MetS)
- inflammatory bowel disease
- irritable bowel syndrome
- allergic diseases
- autoimmune diseases
- cardiovascular diseases
- renal diseases